Therapeutic modulation of prostate cancer metastasis

Future Medicinal Chemistry

Volumn 6, Issue 2, 2014, Pages 223-239

  Krishna, Sankar N ^a   Bergan, Raymond C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; INTEGRIN; MATRIX METALLOPROTEINASE; MICROTUBULE ASSOCIATED PROTEIN 2; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CASE STUDY; CELL ADHESION; CELL INVASION; CELL MIGRATION; CIRCULATING TUMOR CELL; CIRCULATION; DEGRADATION; DISEASE COURSE; EXTRACELLULAR MATRIX; EXTRAVASATION; HUMAN; IMPLANTATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UNITED STATES;

ANTINEOPLASTIC AGENTS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INTEGRINS; MALE; MATRIX METALLOPROTEINASES; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84893163282     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.201     Document Type: Review

References (120)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11-30 (2013
2. Cooperberg MR, Konety BR. Management of localized prostate cancer in men over 65 years. Curr. Opin. Urol. 19(3), 309-314 (2009
3. Carter HB, Albertsen PC, Barry MJ et al. Early detection of prostate cancer: AUA guideline. J. Urol. 190(2), 419-426 (2013
4. Li J, Djenaba JA, Soman A, Rim SH, Master VA. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer 691380 (2012
5. Bubendorf L, Schopfer A, Wagner U et al. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum. Pathol. 31(5), 578-583 (2000
6. Devita VT, Rosenberg SA, Hellman S. Cancer: Principles and Practice of Oncology (7th). Lippincott, Williams and Wilkins, PA, USA (2005
7. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: Innovations for the post-Trial era. Nat. Rev. Cancer 2(9), 657-672 (2002
8. Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr. Opin. Endocrinol. Diabetes Obes. 20(3), 204-209 (2013
9. Jani AB, Hellman S. Early prostate cancer: Clinical decision-making. Lancet 361(9362), 1045-1053 (2003
10. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev. Urol. 9(Suppl. 1), S3-S8 (2007
11. Clarke JM, Armstrong AJ. Novel therapies for the treatment of advanced prostate cancer. Curr. Treat. Options Oncol. 14(1), 109-126 (2013
12. Mitsiades N. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer Res. 73(15), 4599-4605 (2013
13. Attard G, Richards J, De Bono JS. New strategies in metastatic prostate cancer: Targeting the androgen receptor signaling pathway. Clin. Cancer Res. 17(7), 1649-1657 (2011
14. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349(3), 215-224 (2003
15. Gittes RF. Carcinoma of the prostate. N. Engl. J. Med. 324(4), 236-245 (1991
16. Valastyan S, Weinberg RA. Tumor metastasis: Molecular insights and evolving paradigms. Cell 147(2), 275-292 (2011
17. Sugarbaker EV. Some characteristics of metastasis in man. Am. J. Pathol. 97(3), 623-632 (1979
18. Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M, Patel HR. The metastatic cascade in prostate cancer. Surg. Oncol. 15(3), 117-128 (2006
19. Choi IK, Strauss R, Richter M, Yun CO, Lieber A. Strategies to increase drug penetration in solid tumors. Front. Oncol. 3, 193 (2013
20. Bostwick DG. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 78(2), 330-336 (1996
21. Eccles SA, Box C, Court W. Cell migration/invasion assays and their application in cancer drug discovery. Biotechnol. Annu. Rev. 11, 391-421 (2005
22. Pokutta S, Weis WI. Structure and mechanism of cadherins and catenins in cell-cell contacts. Annu. Rev. Cell. Dev. Biol. 23, 237-261 (2007
23. Gonzalez-Amaro R, Sanchez-Madrid F. Cell adhesion molecules: Selectins and integrins. Crit. Rev. Immunol. 19(5-6), 389-429 (1999
24. Suyin PC, Dickinson JL, Holloway AF. Integrins in Prostate Cancer Invasion and Metastasis. In:Advances in Prostate Cancer . Hamilton DG (Ed.). InTech, London, UK (2013
25. Taherian A, Li X, Liu Y, Haas TA. Differences in integrin expression and signaling within human breast cancer cells. BMC Cancer 11, 293 (2011
26. Lee S, Shen Z, Robinson DN, Briggs S, Firtel RA. Involvement of the cytoskeleton in controlling leading-edge function during chemotaxis. Mol. Biol. Cell 21(11), 1810-1824 (2010
27. Frixione E. Recurring views on the structure and function of the cytoskeleton: A 300-year epic. Cell Motil. Cytoskeleton 46(2), 73-94 (2000
28. Cheresh DA, Stupack DG. Regulation of angiogenesis: Apoptotic cues from the ECM. Oncogene 27(48), 6285-6298 (2008
29. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2(3), 161-174 (2002
30. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J. Cell Physiol. 211(1), 19-26 (2007
31. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta 1477(1-2), 267-283 (2000
32. Stegmann TJ. FGF-1: A human growth factor in the induction of neoangiogenesis. Expert Opin. Investig. Drugs 7(12), 2011-2015 (1998
33. Hoeben A, Landuyt B, Highley MS, Wildiers H, van Oosterom AT, de Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56(4), 549-580 (2004
34. Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: Commentary re: AC Lockhart et al. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res. 9(2), 551-554 (2003
35. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 59(7), 1592-1598 (1999
36. Kruck S, Gakis G, Stenzl A. Disseminated and circulating tumor cells for monitoring chemotherapy in urological tumors. Anticancer Res. 31(6), 2053-2057 (2011
37. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J. Oncol. 617421 (2010
38. Nicolson GL. Cancer metastasis: Tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim. Biophys. Acta. 948(2), 175-224 (1988
39. Rice L, Lepler S, Pampo C, Siemann DW. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clin. Exp. Metastasis 29(2), 133-142 (2012
40. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin. Cancer Res. 15(10), 3540-3549 (2009
41. Park SI, Zhang J, Phillips KA et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 68(9), 3323-3333 (2008
42. Guo Z, Dai B, Jiang T et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10(4), 309-319 (2006
43. Yu EY, Wilding G, Posadas E et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 15(23), 7421-7428 (2009
44. Araujo JC, Mathew P, Armstrong AJ et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a Phase 1-2 study. Cancer 118(1), 63-71 (2012
45. Twardowski PW, Beumer JH, Chen CS et al. A Phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs 24(7), 743-753 (2013
46. Araujo JC, Trudel GC, Paliwal P. Long-Term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel. Cancer Manag. Res. 6, 25-30 (2013
47. Breen MJ, Moran DM, Liu W, Huang X, Vary CP, Bergan RC. Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors. PLoS ONE 8(8), e72407 (2013
48. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-b targeted cancer therapy. Int. J. Biol. Sci. 8(7), 964-978 (2012
49. Nagaraj NS, Datta PK. Targeting the transforming growth factor-b signaling pathway in human cancer. Expert Opin. Investig. Drugs 19(1), 77-91 (2010
50. Ao M, Williams K, Bhowmick NA, Hayward SW. Transforming growth factor-b promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res. 66(16), 8007-8016 (2006
51. Pinkas J, Teicher BA. TGF-b in cancer and as a therapeutic target. Biochem. Pharmacol. 72(5), 523-529 (2006
52. Bello-Deocampo D, Tindall DJ. TGF-b-l/Smad signaling in prostate cancer. Curr. Drug Targets 4(3), 197-207 (2003
53. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A. TGF-b and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol. Biol. Cell. 16(4), 1987-2002 (2005
54. Holzbeierlein J, Lal P, Latulippe E et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164(1), 217-227 (2004
55. Craft CS, Romero D, Vary CP, Bergan RC. Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene 26(51), 7240-7250 (2007
56. Lakshman M, Huang X, Ananthanarayanan V et al. Endoglin suppresses human prostate cancer metastasis. Clin. Exp. Metastasis 28(1), 39-53 (2011
57. Romero D, Terzic A, Conley BA et al. Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis 31(3), 359-366 (2010
58. Hau P, Jachimczak P, Schlingensiepen R et al. Inhibition of TGF-b2 with AP 12009 in recurrent malignant gliomas: From preclinical to Phase I/II studies. Oligonucleotides 17(2), 201-212 (2007
59. Saunier EF, Akhurst RJ. TGF b inhibition for cancer therapy. Curr. Cancer Drug Targets 6(7), 565-578 (2006
60. Bogdahn U, Hau P, Stockhammer G et al. Targeted therapy for high-grade glioma with the TGF-b2 inhibitor trabedersen: Results of a randomized and controlled Phase IIb study. Neuro. Oncol. 13(1), 132-142 (2011
61. Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S. Antisense therapeutics for tumor treatment: The TGF-b2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res. 177, 137-150 (2008
62. Muraoka RS, Dumont N, Ritter CA et al. Blockade of TGF-b inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109(12), 1551-1559 (2002
63. Wan X, Li ZG, Yingling JM et al. Effect of transforming growth factor b (TGF-b) receptor I kinase inhibitor on prostate cancer bone growth. Bone 50(3), 695-703 (2012
64. Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-b up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47(5), 1557-1566 (2008
65. Melisi D, Ishiyama S, Sclabas GM et al. LY2109761, a novel transforming growth factor b receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 7(4), 829-840 (2008
66. Zhang M, Kleber S, Rohrich M et al. Blockade of TGF-b signaling by the TGFbR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 71(23), 7155-7167 (2011
67. Zhao BM, Hoffmann FM. Inhibition of transforming growth factor-b1-induced signaling and epithelial-To-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol. Biol. Cell 17(9), 3819-3831 (2006
68. Cuenda A. Mitogen-Activated protein kinase kinase 4 (MKK4). Int. J. Biochem. Cell. Biol. 32(6), 581-587 (2000
69. Stearns ME, Wang M. Type IV collagenase (M(r) 72,000) expression in human prostate. benign and malignant tissue. Cancer Res. 53(4), 878-883 (1993
70. Xu L, Ding Y, Catalona WJ et al. MEK4 function, genistein treatment, and invasion of human prostate cancer cells. J. Natl Cancer Inst. 101(16), 1141-1155 (2009
71. Huang X, Chen S, Xu L et al. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 65(8), 3470-3478 (2005
72. Takimoto CH, Glover K, Huang X et al. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol. Biomarkers Prev. 12(11 Pt 1), 1213-1221 (2003
73. Matsumoto T, Kinoshita T, Kirii Y, Yokota K, Hamada K, Tada T. Crystal structures of MKK4 kinase domain reveal that substrate peptide binds to an allosteric site and induces an auto-inhibition state. Biochem. Biophys. Res. Commun. 400(3), 369-373 (2010
74. Kim KB, Kefford R, Pavlick AC et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31(4), 482-489 (2013
75. Krishna SN, Luan C-H, Mishra RK et al. A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated kinase kinase 4. PLoS ONE 8(12), e81504 (2013
76. Liu Z, Wang F, Chen X. Integrin a(v)b(3)-Targeted cancer therapy. Drug Dev. Res. 69(6), 329-339 (2008
77. Mccabe NP, De S, Vasanji A, Brainard J, Byzova TV. Prostate cancer specific integrin avb3 modulates bone metastatic growth and tissue remodeling. Oncogene 26(42), 6238-6243 (2007
78. Xiong JP, Stehle T, Diefenbach B et al. Crystal structure of the extracellular segment of integrin a Vb3. Science 294(5541), 339-345 (2001
79. Delbaldo C, Raymond E, Vera K et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against avb3 integrin receptor, in patients with advanced solid tumors. Invest. New Drugs 26(1), 35-43 (2008
80. Mcneel DG, Eickhoff J, Lee FT et al. Phase I trial of a monoclonal antibody specific for avb3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res. 11(21), 7851-7860 (2005
81. Hersey P, Sosman J, O'day S et al. A randomized Phase 2 study of etaracizumab, a monoclonal antibody against integrin a(v)b(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer 116(6), 1526-1534 (2010
82. Almokadem S, Belani CP. Volociximab in cancer. Expert Opin. Biol. Ther. 12(2), 251-257 (2012
83. Kuwada SK. Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr. Opin. Mol. Ther. 9(1), 92-98 (2007
84. Ramakrishnan V, Bhaskar V, Law DA et al. Preclinical evaluation of an anti-A5b1 integrin antibody as a novel anti-Angiogenic agent. J. Exp. Ther. Oncol. 5(4), 273-286 (2006
85. Ricart AD, Tolcher AW, Liu G et al. Volociximab, a chimeric monoclonal antibody that specifically binds a5b1 integrin: A Phase I, pharmacokinetic, and biological correlative study. Clin. Cancer Res. 14(23), 7924-7929 (2008
86. Khalili P, Arakelian A, Chen G et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 5(9), 2271-2280 (2006
87. Trikha M, Zhou Z, Nemeth JA et al. CNTO 95, a fully human monoclonal antibody that inhibits av integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer 110(3), 326-335 (2004
88. Heidenreich A, Rawal SK, Szkarlat K et al. A randomized, double-blind, multicenter, Phase II study of a human monoclonal antibody to human anu integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann. Oncol. 24(2), 329-336 (2013
89. Slack-Davis JK, Parsons JT. Emerging views of integrin signaling: Implications for prostate cancer. J. Cell Biochem. 91(1), 41-46 (2004
90. Lin TH, Tan TW, Tsai TH et al. d-pinitol inhibits prostate cancer metastasis through inhibition of aVb3 integrin by modulating FAK, c-Src and NF-kB pathways. Int. J. Mol. Sci. 14(5), 9790-9802 (2013
91. Della Porta P, Soeltl R, Krell HW et al. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo. Anticancer Res. 19(5B), 3809-3816 (1999
92. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295(5564), 2387-2392 (2002
93. Fingleton B. MMPs as therapeutic targets - still a viable option? Semin. Cell. Dev. Biol. 19(1), 61-68 (2008
94. Desgrosellier JS, Cheresh DA. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 10(1), 9-22 (2010
95. Rupp PA, Visconti RP, Czirok A, Cheresh DA, Little CD. Matrix metalloproteinase 2-integrin a(v)b3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: A computational time-lapse study. Mol. Biol. Cell. 19(12), 5529-5540 (2008
96. Brown S, Bernardo MM, Li Z-H et al. Potent and selective mechanism-based inhibition of gelatinases. J. Am. Chem. Soc. 122(28), 6799-6800 (2000
97. Bonfil RD, Sabbota A, Nabha S et al. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int. J. Cancer 118(11), 2721-2726 (2006
98. Kruger A, Arlt MJ, Gerg M et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res. 65(9), 3523-3526 (2005
99. Devy L, Dransfield DT. New strategies for the next generation of matrix-metalloproteinase inhibitors: Selectively targeting membrane-Anchored mmps with therapeutic antibodies. Biochem. Res. Int. 2011, 191670 (2011
100. Devy L, Huang L, Naa L et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 69(4), 1517-1526 (2009
101. Atkinson JM, Falconer RA, Edwards DR et al. Development of a novel tumor-Targeted vascular disrupting agent activated by membrane-Type matrix metalloproteinases. Cancer Res. 70(17), 6902-6912 (2010
102. Scher HI, Jia X, De Bono JS et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol. 10(3), 233-239 (2009
103. Hughes AD, King MR. Nanobiotechnology for the capture and manipulation of circulating tumor cells. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4(3), 291-309 (2012
104. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: Approaches to isolation and characterization. J. Cell Biol. 192(3), 373-382 (2011
105. Liljefors M, Nilsson B, Fagerberg J, Ragnhammar P, Mellstedt H, Frodin JE. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. Int. J. Oncol. 26(6), 1581-1589 (2005
106. Faltas B. Targeting hematogenous spread of circulating tumor cells by a chemotactic drug-eluting IVC filter to prevent pulmonary and systemic metastasis. Med. Hypotheses 74(4), 668-669 (2010
107. Marangoni E, Lecomte N, Durand L et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br. J. Cancer 100(6), 918-922 (2009
108. Subramaniam V, Vincent IR, Gilakjan M, Jothy S. Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp. Mol. Pathol. 83(3), 332-340 (2007
109. Nelson DM, Peterson AC. Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer. Aging Male 13(2), 120-123 (2010
110. Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases. Semin. Oncol. 28(2 Suppl. 6), 11-16 (2001
111. Ibrahim A, Scher N, Williams G et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin. Cancer Res. 9(7), 2394-2399 (2003
112. Wong BR, Rho J, Arron J et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-Terminal kinase in T cells. J. Biol. Chem. 272(40), 25190-25194 (1997
113. Schramek D, Leibbrandt A, Sigl V et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320), 98-102 (2010
114. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2), 165-176 (1998
115. Pageau SC. Denosumab. MAbs 1(3), 210-215 (2009
116. Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-Telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized Phase II trial. J. Urol. 182(2), 509-515; discussion 515-516 (2009
117. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 377(9768), 813-822 (2011
118. Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a Phase 3, randomised, placebo-controlled trial. Lancet 379(9810), 39-46 (2012
119. Beattie BJ, Smith-Jones PM, Jhanwar YS et al. Pharmacokinetic assessment of the uptake of 16b-18F-fluoro-5a-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J. Nucl. Med. 51(2), 183-192 (2010
120. Schuster DM, Savir-Baruch B, Nieh PT et al. Detection of recurrent prostate carcinoma with anti-1-Amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology 259(3), 852-861 (2011